Abstract
National health-care expenses and R&D expenditure of pharmaceutical industry have risen in Japan, while the economic growth and the extension of total sales of pharmaceuticals have shrunk in recent years. On the other hand, the amount of the sales and potentiality of discovering innovative drugs in the western industry are growing year by year. Most recently, some of the domestic companies have started to discover the innovative drugs using genome technology. Thus, these circumstances surrounding the pharmaceutical industry are drastically changing in Japan. These situations will be described in this paper. Generally speaking, pharmaceutical information is generated from broad fields which start from drug-discovery research to post marketing surveillance (PMS). Thus, we can call " information accumulated compound " to the drugs. Among them, the PMS information is usually called "drug information", which is the most important knowledge for the patient's safety during the drug use. Here, the speaker will survey the activities of the drug information in Japan. >From the viewpoint of the medicinal chemistry, the package inserts-information including the PMS would be useful knowledge for the drug design. The speaker will talk about a concept "Spiral Circulation of Drug Information" for the drug design.
